EY’s Abhay Bangi highlights the key trends across the ASEAN life sciences space, how the COVID-19 pandemic has accelerated them, and charts Singapore’s course towards becoming a world-class biotech investment destination.
Value-Based healthcare in this part of the world will be implemented in different ways. It will come less through contracts, but more through pricing regulations
Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…
Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and…
See our Cookie Privacy Policy Here